These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


Pubmed for Handhelds

PUBMED FOR HANDHELDS

Journal Abstract Search

604 related items for PubMed ID: 12478408

  • 1. A randomized prospective controlled trial of oral ganciclovir versus oral valacyclovir for prophylaxis of cytomegalovirus disease after renal transplantation.
    Reischig T, Opatrny K, Bouda M, Treska V, Jindra P, Svecova M.
    Transpl Int; 2002 Dec; 15(12):615-22. PubMed ID: 12478408
    [Abstract] [Full Text] [Related]

  • 2. Prospective comparison of valacyclovir and oral ganciclovir for prevention of cytomegalovirus disease in high-risk renal transplant recipients.
    Reischig T, Opatrný K, Treska V, Mares J, Jindra P, Svecová M.
    Kidney Blood Press Res; 2005 Dec; 28(4):218-25. PubMed ID: 16043964
    [Abstract] [Full Text] [Related]

  • 3. A comparative randomised study of valacyclovir vs. oral ganciclovir for cytomegalovirus prophylaxis in renal transplant recipients.
    Pavlopoulou ID, Syriopoulou VP, Chelioti H, Daikos GL, Stamatiades D, Kostakis A, Boletis JN.
    Clin Microbiol Infect; 2005 Sep; 11(9):736-43. PubMed ID: 16104989
    [Abstract] [Full Text] [Related]

  • 4. Prevention of primary cytomegalovirus disease in organ transplant recipients with oral ganciclovir or oral acyclovir prophylaxis.
    Rubin RH, Kemmerly SA, Conti D, Doran M, Murray BM, Neylan JF, Pappas C, Pitts D, Avery R, Pavlakis M, Del Busto R, DeNofrio D, Blumberg EA, Schoenfeld DA, Donohue T, Fisher SA, Fishman JA.
    Transpl Infect Dis; 2000 Sep; 2(3):112-7. PubMed ID: 11429021
    [Abstract] [Full Text] [Related]

  • 5. Valacyclovir for cytomegalovirus prophylaxis reduces the risk of acute renal allograft rejection.
    Reischig T, Jindra P, Mares J, Cechura M, Svecová M, Hes O, Opatrný K, Treska V.
    Transplantation; 2005 Feb 15; 79(3):317-24. PubMed ID: 15699762
    [Abstract] [Full Text] [Related]

  • 6. The impact of cytomegalovirus disease and asymptomatic infection on acute renal allograft rejection.
    Reischig T, Jindra P, Svecová M, Kormunda S, Opatrný K, Treska V.
    J Clin Virol; 2006 Jun 15; 36(2):146-51. PubMed ID: 16531113
    [Abstract] [Full Text] [Related]

  • 7. Valacyclovir for the prevention of cytomegalovirus disease after renal transplantation. International Valacyclovir Cytomegalovirus Prophylaxis Transplantation Study Group.
    Lowance D, Neumayer HH, Legendre CM, Squifflet JP, Kovarik J, Brennan PJ, Norman D, Mendez R, Keating MR, Coggon GL, Crisp A, Lee IC.
    N Engl J Med; 1999 May 13; 340(19):1462-70. PubMed ID: 10320384
    [Abstract] [Full Text] [Related]

  • 8. Randomized controlled trial of oral ganciclovir versus oral acyclovir after induction with intravenous ganciclovir for long-term prophylaxis of cytomegalovirus disease in cytomegalovirus-seropositive liver transplant recipients.
    Winston DJ, Busuttil RW.
    Transplantation; 2003 Jan 27; 75(2):229-33. PubMed ID: 12548129
    [Abstract] [Full Text] [Related]

  • 9. A randomized prospective trial of oral versus intravenous ganciclovir for prophylaxis of cytomegalovirus infection and disease in high-risk kidney recipients.
    Nafar M, Pezeshki ML, Farrokhi F, Einollahi B, Pour-Reza-Gholi F, Firouzan A, Farhangi S.
    Transplant Proc; 2005 Sep 27; 37(7):3053-5. PubMed ID: 16213302
    [Abstract] [Full Text] [Related]

  • 10. Randomized comparison of oral valacyclovir and intravenous ganciclovir for prevention of cytomegalovirus disease after allogeneic bone marrow transplantation.
    Winston DJ, Yeager AM, Chandrasekar PH, Snydman DR, Petersen FB, Territo MC, Valacyclovir Cytomegalovirus Study Group.
    Clin Infect Dis; 2003 Mar 15; 36(6):749-58. PubMed ID: 12627359
    [Abstract] [Full Text] [Related]

  • 11. Valacyclovir for the prevention of cytomegalovirus infection after allogeneic stem cell transplantation: a single institution retrospective cohort analysis.
    Vusirikala M, Wolff SN, Stein RS, Brandt SJ, Morgan DS, Greer JP, Schuening FG, Dummer JS, Goodman SA.
    Bone Marrow Transplant; 2001 Aug 15; 28(3):265-70. PubMed ID: 11535994
    [Abstract] [Full Text] [Related]

  • 12. Low-dose valaciclovir prophylaxis against cytomegalovirus disease in renal transplant recipients.
    Reddy SP, Handa A, Tan L, Devaney A, Hughes D, Mason P, Friend PJ, Darby CR.
    Transpl Int; 2003 Oct 15; 16(10):726-9. PubMed ID: 12827230
    [Abstract] [Full Text] [Related]

  • 13. 24-week oral ganciclovir prophylaxis in kidney recipients is associated with reduced symptomatic cytomegalovirus disease compared to a 12-week course.
    Doyle AM, Warburton KM, Goral S, Blumberg E, Grossman RA, Bloom RD.
    Transplantation; 2006 Apr 27; 81(8):1106-11. PubMed ID: 16641594
    [Abstract] [Full Text] [Related]

  • 14. Oral ganciclovir in pediatric transplant recipients: a pharmacokinetic study.
    Pescovitz MD, Brook B, Jindal RM, Leapman SB, Milgrom ML, Filo RS.
    Clin Transplant; 1997 Dec 27; 11(6):613-7. PubMed ID: 9408695
    [Abstract] [Full Text] [Related]

  • 15. Efficacy of oral ganciclovir in prevention of cytomegalovirus infection in post-kidney transplant patients.
    Ahsan N, Holman MJ, Yang HC.
    Clin Transplant; 1997 Dec 27; 11(6):633-9. PubMed ID: 9408699
    [Abstract] [Full Text] [Related]

  • 16. [Effectiveness of preemptive therapy with ganciclovir in recipients of renal transplants at high risk (R-/D+) for the development of cytomegalovirus disease].
    Aranda-Verástegui F, Alberú J, Soto-Ramírez LE, González-Aguirre H, Muñoz Trejo T, Mancilla E, Díliz H, Correa-Rotter R, Sierra-Madero J.
    Rev Invest Clin; 2002 Dec 27; 54(3):198-203. PubMed ID: 12183888
    [Abstract] [Full Text] [Related]

  • 17. Pharmacoeconomic impact of different regimens to prevent cytomegalovirus infection in renal transplant recipients.
    Kielberger L, Bouda M, Jindra P, Reischig T.
    Kidney Blood Press Res; 2012 Dec 27; 35(6):407-16. PubMed ID: 22584353
    [Abstract] [Full Text] [Related]

  • 18. Randomized clinical trial of ganciclovir vs acyclovir for prevention of cytomegalovirus antigenemia after allogeneic transplantation.
    Burns LJ, Miller W, Kandaswamy C, DeFor TE, MacMillan ML, Van Burik JA, Weisdorf DJ.
    Bone Marrow Transplant; 2002 Dec 27; 30(12):945-51. PubMed ID: 12476289
    [Abstract] [Full Text] [Related]

  • 19. Intragraft cytomegalovirus infection: a randomized trial of valacyclovir prophylaxis versus pre-emptive therapy in renal transplant recipients.
    Reischig T, Nemcová J, Vanecek T, Jindra P, Hes O, Bouda M, Treska V.
    Antivir Ther; 2010 Dec 27; 15(1):23-30. PubMed ID: 20167988
    [Abstract] [Full Text] [Related]

  • 20. Randomized controlled trial of sequential intravenous and oral ganciclovir versus prolonged intravenous ganciclovir for long-term prophylaxis of cytomegalovirus disease in high-risk cytomegalovirus-seronegative liver transplant recipients with cytomegalovirus-seropositive donors.
    Winston DJ, Busuttil RW.
    Transplantation; 2004 Jan 27; 77(2):305-8. PubMed ID: 14742998
    [Abstract] [Full Text] [Related]

    Page: [Next] [New Search]
    of 31.